The proposed studies continue a long interest in hemostatic mechanisms and related phenomena, now stressing the role of cells. Emphasis will be placed upon newly discovered inhibitory properties of peripheral blood mononuclear cells against the activation of Hageman factor (HF, factor XII). Current experiments are aimed at its purification and biologic role in maintaining the fluidity of blood; a similar property has been detected in supernates of endothelial cell cultures. To facilitate these studies, improved purification methods for HF and high molecular weight kininogen are under development. Hormonal regulation of the plasma titer of HF will be explored in the light of evidence that estrogens, prolactin and corticosteroids increase the titer. Since HF and prolactin synthesis may be determined by genes on chromosome 6, linkage between these genes will be sought. Studies of the acquired immunodeficiency syndrome in classic hemophilia will be continued, as well as examination of the inhibition of phytohemagglutinin-induced lymphocyte proliferation and interleukin-2 liberation by fractions of plasma in lyophilized antihemophilic factor (factor VIII) preparations. Other experiments will examine properties of an inhibitor of the generation of monocyte coagulant activity elaborated by endothelial cells; factors modulating tissue plasminogen activator produced by melanoma cells; the effects of fibrinogen degradation products upon human neutrophil function; and characterization of a monocyte-derived growth factor and its relationship to other growth factors. As always, vigorous attempts will be made to learn more about the physiology of hemostasis and thrombosis through the study of suitable patients.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
2R01HL001661-34
Application #
3334101
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1975-09-01
Project End
1990-08-31
Budget Start
1985-09-01
Budget End
1986-08-31
Support Year
34
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Perales, J C; Ferkol, T; Beegen, H et al. (1994) Gene transfer in vivo: sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. Proc Natl Acad Sci U S A 91:4086-90
Bogdan, C J; Strauss, M; Ratnoff, O D (1994) Airway obstruction in hemophilia (factor VIII deficiency): a 28-year institutional review. Laryngoscope 104:789-94
Pettee, A D; Wasserman, B A; Adams, N L et al. (1994) Familial Sneddon's syndrome: clinical, hematologic, and radiographic findings in two brothers. Neurology 44:399-405
Ratnoff, O D; Gleich, G J; Shurin, S B et al. (1993) Inhibition of the activation of hageman factor (factor XII) by eosinophils and eosinophilic constituents. Am J Hematol 42:138-45
Ferkol, T; Lindberg, G L; Chen, J et al. (1993) Regulation of the phosphoenolpyruvate carboxykinase/human factor IX gene introduced into the livers of adult rats by receptor-mediated gene transfer. FASEB J 7:1081-91
Stein, J; Ratnoff, O D (1993) An inhibitor of antihemophilic factor (factor VIII) in an 18-month-old nonhemophilic child. Am J Pediatr Hematol Oncol 15:346-50
Ratnoff, O D (1993) Some complications of the therapy of hemorrhagic disorders. Dis Mon 39:301-54
Ryder, J; Everson, B; Jentoft, J et al. (1993) The effect of chemical modification of basic amino acid residues on the activation and amidolytic activity of Hageman factor (factor XII). J Lab Clin Med 122:697-702
Foster, C B; Flanigan, T P; DeStigter, K K et al. (1992) Inhibition of the activation of Hageman factor (factor XII) by extracts of Schistosoma mansoni. J Lab Clin Med 120:735-9
Toossi, Z; Sedor, J R; Mettler, M A et al. (1992) Induction of expression of monocyte interleukin 1 by Hageman factor (factor XII). Proc Natl Acad Sci U S A 89:11969-72

Showing the most recent 10 out of 49 publications